Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PAM | P19021 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27369755 | 0.82 | TDP1 (0.58) | CES1ALDH1A1MAPK1TSHRSMN1; SMN2 | |
| SCHEMBL248113 | 0.82 | ALDH1A1 (0.65) | CES1ALDH1A1MAPK1L3MBTL1PAM | |
| SCHEMBL6261030 | 0.81 | TSHR (0.53) | CES1ALDH1A1MAPK1L3MBTL1PAM | |
| SCHEMBL4647864 | 0.81 | ALDH1A1 (0.52) | CES1ALDH1A1MAPK1L3MBTL1PAM | |
| SCHEMBL12045337 | 0.81 | CES1 (0.46) | CES1ALDH1A1MAPK1L3MBTL1PAM | |
| Water SCHEMBL27403515 | 0.81 | TDP1 (0.56) | CES1ALDH1A1MAPK1TSHRSMN1; SMN2 | |
| SCHEMBL4658964 | 0.80 | CES1 (0.47) | CES1ALDH1A1MAPK1L3MBTL1TSHR | |
| SCHEMBL7562503 | 0.80 | KMT2A (0.52) | ALDH1A1L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL4642466 | 0.79 | TSHR (0.50) | CES1ALDH1A1MAPK1L3MBTL1PAM | |
| SCHEMBL11606595 | 0.79 | ALDH1A1 (0.49) | CES1ALDH1A1MAPK1L3MBTL1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216430-A1 | CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-07-09 | — | — | US | disclosed |
| WO-2019060998-A1 | CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-04-04 | — | — | WO | disclosed |
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-10 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| CN-102260151-A | Preparation method of 1,1,1,5,5,5-hexafluoro acetylacetone | XI AN CAIJING OPTO ELECTRICAL SCEIENCE & TECHNOLOGY CO LTD | 2011-11-30 | — | — | CN | disclosed |
| WO-2010129048-A2 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| CN-1256326-C | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| CN-1209745-A | Method of inhibiting colon tumors | LILLY CO ELI (US) | 1999-03-03 | — | — | CN | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | CES1 3117/4885ALDH1A1 4010/4885MAPK1 2307/4885 |
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | HTR2C, HTR2A, HTR3C | CES1 2203/4885ALDH1A1 3621/4885MAPK1 3795/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | CES1 3117/4885ALDH1A1 4010/4885MAPK1 2307/4885 |
| US-20200216430-A1 | CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT | CYBB, NOX4, NOX3 | CES1 2614/4885ALDH1A1 670/4885MAPK1 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.